Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$337.42 +1.8%	$346.62	$267.83 ▼ $391.29	$182.10B	0.44	2.75 million shs	2.00 million shs
AZN Astrazeneca	$189.88 +1.3%	$191.76	$137.23 ▼ $212.71	$294.48B	0.26	2.63 million shs	2.19 million shs
BIIB Biogen	$189.47 +0.9%	$185.42	$121.05 ▼ $205.97	$27.97B	0.19	1.30 million shs	1.47 million shs
MRNA Moderna	$47.26 -1.8%	$51.00	$22.28 ▼ $59.55	$18.75B	1.05	9.63 million shs	4.78 million shs

Don't wait for the SpaceX IPO

The space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.25%	-1.45%	-5.31%	-11.70%	+20.57%
AZN Astrazeneca	+1.52%	-0.11%	-6.65%	-10.13%	+34.08%
BIIB Biogen	-1.45%	-8.18%	+2.43%	-2.23%	+43.85%
MRNA Moderna	+5.25%	-4.56%	-11.85%	-3.18%	+71.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$337.42 +1.8%	$346.62	$267.83 ▼ $391.29	$182.10B	0.44	2.75 million shs	2.00 million shs
AZN Astrazeneca	$189.88 +1.3%	$191.76	$137.23 ▼ $212.71	$294.48B	0.26	2.63 million shs	2.19 million shs
BIIB Biogen	$189.47 +0.9%	$185.42	$121.05 ▼ $205.97	$27.97B	0.19	1.30 million shs	1.47 million shs
MRNA Moderna	$47.26 -1.8%	$51.00	$22.28 ▼ $59.55	$18.75B	1.05	9.63 million shs	4.78 million shs

Don't wait for the SpaceX IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.25%	-1.45%	-5.31%	-11.70%	+20.57%
AZN Astrazeneca	+1.52%	-0.11%	-6.65%	-10.13%	+34.08%
BIIB Biogen	-1.45%	-8.18%	+2.43%	-2.23%	+43.85%
MRNA Moderna	+5.25%	-4.56%	-11.85%	-3.18%	+71.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$355.19	5.27% Upside
AZN Astrazeneca	2.85	Moderate Buy	$205.33	8.14% Upside
BIIB Biogen	2.52	Moderate Buy	$215.62	13.80% Upside
MRNA Moderna	1.84	Reduce	$35.73	-24.39% Downside

Current Analyst Ratings Breakdown

Latest AZN, AMGN, BIIB, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2026	AZN Astrazeneca	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
5/20/2026	AMGN Amgen	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$400.00 ➝ $375.00
5/15/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$214.00 ➝ $225.00
5/15/2026	BIIB Biogen	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
5/14/2026	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/14/2026	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$432.00 ➝ $427.00
5/14/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/14/2026	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$275.00 ➝ $300.00
5/13/2026	AMGN Amgen	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$410.00 ➝ $390.00
5/13/2026	AZN Astrazeneca	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/7/2026	AMGN Amgen	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	4.95	$34.50 per share	9.78	$17.03 per share	19.81
AZN Astrazeneca	$60.44B	4.87	$13.30 per share	14.28	$30.55 per share	6.22
BIIB Biogen	$9.89B	2.83	$22.50 per share	8.42	$126.33 per share	1.50
MRNA Moderna	$1.94B	9.65	N/A	N/A	$18.67 per share	2.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$14.37	23.48	14.32	3.32	20.96%	137.41%	13.28%	8/4/2026 (Estimated)
AZN Astrazeneca	$10.23B	$6.66	28.51	16.44	1.52	17.19%	30.86%	12.68%	7/27/2026 (Estimated)
BIIB Biogen	$1.29B	$9.32	20.33	11.44	1.68	13.81%	12.83%	8.01%	7/30/2026 (Estimated)
MRNA Moderna	-$2.82B	-$8.15	N/A	N/A	N/A	-143.55%	-26.64%	-19.32%	7/31/2026 (Estimated)

Latest AZN, AMGN, BIIB, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2026	Q1 2026	MRNA Moderna	-$3.02	-$3.40	-$0.38	-$3.40	$236.37 million	$389.00 million
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion
4/29/2026	Q1 2026	AZN Astrazeneca	$2.52	$2.58	+$0.06	$0.9850	$14.93 billion	$15.29 billion
4/29/2026	Q1 2026	BIIB Biogen	$2.95	$3.57	+$0.62	$2.15	$2.29 billion	$2.48 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	2.99%	+8.27%	70.15%	14 Years
AZN Astrazeneca	$4.34	2.29%	+2.30%	65.17%	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Latest AZN, AMGN, BIIB, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2026	AMGN Amgen	quarterly	$2.52	3.09%	5/15/2026	5/15/2026	6/5/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	5.65	1.26	1.01
AZN Astrazeneca	0.52	0.91	0.71
BIIB Biogen	0.34	3.06	2.41
MRNA Moderna	0.08	2.41	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
AZN Astrazeneca	20.35%
BIIB Biogen	87.93%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
AZN Astrazeneca	N/A
BIIB Biogen	0.25%
MRNA Moderna	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	539.68 million	535.10 million	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
BIIB Biogen	7,500	147.64 million	147.27 million	Optionable
MRNA Moderna	4,700	396.79 million	353.93 million	Optionable

AZN, AMGN, BIIB, and MRNA Headlines

Recent News About These Companies

MRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu Shot

1 hour ago | stocktwits.comS

Moderna, Merck cancer combo cuts melanoma spread risk at five years

3 hours ago | reuters.com

US FDA to hold expert committee meeting to review Moderna's flu vaccine

May 21 at 1:19 PM | msn.com

Moderna to face FDA AdCom review for flu shot

May 21 at 1:19 PM | msn.com

Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now

May 21 at 9:36 AM | 247wallst.com

Pfizer, Moderna COVID vaccines 70% to 76% effective against severe illness in kids in 2022, data suggest

May 19 at 12:51 AM | cidrap.umn.eduC

HHS cancels funding for Moderna vaccines to fight pandemic flu

May 19 at 2:48 PM | msn.com

Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

May 19 at 1:03 PM | seekingalpha.com

Moderna (NASDAQ:MRNA) President Stephen Hoge Sells 53,336 Shares

May 19 at 4:01 AM | insidertrades.com

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates

May 18 at 8:02 AM | freep.comF

Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates

May 17, 2026 | freep.comF

Assessing Moderna (MRNA) Valuation After Flu Vaccine Trial Success And Hantavirus Research Attention

May 16, 2026 | finance.yahoo.com

Hantavirus: Is there a risk of another pandemic?

May 16, 2026 | finance.yahoo.com

VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 23,550 Shares of Moderna, Inc. $MRNA

May 16, 2026 | marketbeat.com

Slowed But Not Stalled: The Future of mRNA Vaccine Research

May 14, 2026 | the-scientist.comT

Moderna Recognized by TIME as One of the World’s Most Impactful Companies

May 13, 2026 | usatoday.com

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

May 13, 2026 | fool.com

Moderna (MRNA) Shares Skyrocket, What You Need To Know

May 13, 2026 | finance.yahoo.com

Moderna, Inc.: Moderna Recognized by TIME as One of the World's Most Impactful Companies

May 12, 2026 | finanznachrichten.de

Moderna Recognized by TIME as One of the World's Most Impactful Companies

May 12, 2026 | finance.yahoo.com

Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AZN, AMGN, BIIB, and MRNA Company Descriptions

Amgen NASDAQ:AMGN

$337.42 +5.85 (+1.76%)

Closing price 04:00 PM Eastern

Extended Trading

$337.32 -0.10 (-0.03%)

As of 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Astrazeneca NYSE:AZN

$189.88 +2.42 (+1.29%)

Closing price 03:59 PM Eastern

Extended Trading

$189.25 -0.63 (-0.33%)

As of 07:23 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Biogen NASDAQ:BIIB

$189.47 +1.67 (+0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$186.38 -3.09 (-1.63%)

As of 07:45 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Moderna NASDAQ:MRNA

$47.26 -0.86 (-1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$47.25 -0.01 (-0.02%)

As of 07:58 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZN, AMGN, BIIB, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZN, AMGN, BIIB, and MRNA Earnings

Compare Dividends

Latest AZN, AMGN, BIIB, and MRNA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZN, AMGN, BIIB, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AZN, AMGN, BIIB, and MRNA Company Descriptions

Amgen NASDAQ:AMGN

Astrazeneca NYSE:AZN

Biogen NASDAQ:BIIB

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools